Independent research and treatment center City of Hope National Medical Center said on 21 September that it has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor (CLTX-CAR) T-cell therapy to Chimeric Therapeutics Ltd.
Australia-based Chimeric obtained the exclusive worldwide rights to develop and commercialize certain patents relating to City of Hope’s CLTX-CAR T...